Skip to main content
editorial
. 2023 May 15;18(6):699–701. doi: 10.2215/CJN.0000000000000171

Figure 1.

Figure 1

Choosing a novel aggressive approach over the conventional liberal approach in treating IgA nephropathy might avoid kidney failure in patient's expected lifetime. *In clinical trials, not approved yet. ACEi, angiotensin‐converting enzyme inhibitor; APRIL, a proliferation-inducing ligand; ARB, angiotensin receptor blocker; MMF, mycophenolate mofetil; SGLT2i, sodium‐glucose cotransporter 2 inhibitor.